A Longstanding Academic-Nonprofit Collaboration Gives Rise to an ALS Drug Company

RARECast - En podcast af RARECast - Torsdage

Prøv Podimo gratis! i 30 dage

Et univers fyldt med hundredvis af eksklusive podcasts & lydbøger, klik her for at prøve

Kategorier:

Stan Abel, CEO of ProJenX, about ALS, the company’s lead therapeutic candidate prosetin, and the company’s ongoing relationship with Project ALS and Columbia University.

Visit the podcast's native language site